Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Second sale today for $0.86 five part from 6.32pm to 6.42pm.
This the buy on 18/4/24 for $0.805.
0.805 to 0.86 = 7% approx.
The buy a 46% deal size .
Not quite as much money gain as the first today .
The 4 Analysts still expect the price to increase $6.667
Break-Even Price 2.0591
Sold last buy back saw 5 % up traveling home at 3.30pm .
Set as last weeks $0.81 target strait through $0.8205 .
Topping out 0.846 just after my sale.
Placed a further order to sell .
0.75 to 0.8205 = 9.4% exactly .
The buy only 42.8 % deal size , made a couple of pounds more then the 9.4% in cash terms .
Ex rate must have improved .
Fx 1.237 for the buy on 19th
Fx 1.2529 for today's sell.
25% down today early doors low 14.5p , spread 2%
90 posts here to 9am.
Some pointing at MaryBr190 a bull in recent weeks here , after concerning 7am RNS debt for equity .
Just sent email to broker .
NoelShempsky just seen I paid stamp tax .
I do not pay it on others and if it was Irish would be twice as much .
Is it AIM ?
Thanks again Bermudashorts
I have just kept my C4X the ones in the ISA were at the bigger loss , they will be transferd and held in the non ISA now.
As a side if they were ever to go bust , I wondered if you could offset against gains in ordinary acc .
First top up here for a wile that has not got even cheaper after 10 days .
Redmile Group, LLC
They still have a large holding in Scancell ( SCLP ) 29% which they increased by 12% 20/12/23 from previous 17%
RA Capital I read went on a Buying Spree over the last month , as did other hedge funds to a lesser extent in sector.
RA Capital’s largest new positions are Dyne Therapeutics, a clinical-stage biotech company that is innovating muscle-targeted therapeutics for genetic diseases, and Edgewise Therapeutics, a muscle disease biopharmaceuticals company. They rank 16th and 18th, respectively, in the U.S. portfolio.
They added during the rise here , the rise before the add was from the $5.85 low November to the $36 notice of adding April .
They have inside knowledge .
5.85 to 36 = 500 %
What a timely top up buy in Janux Therapeutics was $52.65 on 12/4/2024 it was up 10 times from 9th November 2023 when $5.85 a 5 year low , they increased position by 15 % last few weeks when price was around $36 1/4/2024.
36 to 52.65 = 46%
April 23, 2024
The biopharma specialist has made a flurry of major new purchases in recent weeks.
Biopharma hedge funds have been on a buying spree the past several weeks. Many of them reported in regulatory filings that they have initiated positions of at least 5 percent in individual stocks or boosted positions to well in excess of 5 percent of outstanding shares.
No firm, however, has been nearly as aggressive as RA Capital Management. In just the past four weeks, it has filed seven initial 13G or 13D documents indicating new investments of 5 percent or more. It also filed amended documents saying it has added to positions in at least four companies that are now holdings of 5 percent or more. Two of the new positions currently rank among the firm’s top-18 holdings, and three stocks in which RA Capital increased existing stakes were catapulted into the firm’s top eight.
This flurry of activity is unusual among life sciences and biopharma hedge funds, which rarely shuffle their portfolio’s largest positions from quarter to quarter. They are generally more of a buy-and-hold crowd, betting on firms they believe have the next drugs with the potential to receive FDA approval. Of course, given these fledgling companies’ small market caps, it does not take much capital to reach the 5 percent that triggers a 13D or 13G filing.
RA Capital is headed by founder Peter Kolchinsky and managing partner Rajeev Shah. As Institutional Investor previously reported, its hedge fund is up 14 percent for the year through March.
With the recent transactions, three stocks have moved onto the firm’s top-ten list.
Janux Therapeutics is the firm’s fourth-largest long, representing 5.72 percent of RA Capital’s U.S. common stock assets after the stake was boosted by more than 15 percent. The hedge fund firm now owns about 20 percent of the total shares outstanding. It is no stranger to Janux, as it was a major venture capital shareholder before the company went public in 2021. Janux is designing T cell immunotherapies that will kill tumors without impacting healthy tissue.
89bio is the seventh-largest long since RA Capital expanded its stake by nearly 25 percent. The hedge fund now has more than 15 percent of the clinical-stage biopharmaceuticals company, which develops therapies for liver and cardiometabolic diseases.
And Tyra Biosciences is the eighth-largest long after the firm recently lifted its stake by about 45 percent. RA Capital now owns more than 25 percent of the total shares. Tyra describes itself as a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in fibroblast growth factor receptor biology.
Redmile Group, LLC
Sold out of these on 31/12 /2022 & Jazz pharmaceuticals 30/9/23 .
They still have a large holding in Scancell ( SCLP ) 29% which they increased by 12% 20/12/23 from previous 17%
Dannatt , what do you mean ?
My broker shows a bep of 502p , so a gain for me here that does not seem to of happen often over passed three years.
Looked at dealing history with ( D )
DARKTRACE (WI)
16/08/2022 Sell 520.0
19/05/2022 Buy 319.00
02/11/2021 Buy 670.00
27/10/2021 Buy 700.00
Hindsight first bought on the dip from the spike to 985p 28/9/21 ( a tip maybe from barc )
High since my first buy 19/8/22 just after my sell at 542p..that was the correct call until yesterday .
One were more averaging down would have worked out as lows were 210p January this year.
When will these two close these positions .
Open Short Positions in Darktrace
Fund........................................................ % Short Change Date Changed
Cadian Capital Management, Lp.............. 0.53%..... 0.00%.... 24 Apr 2024
Qube Research & Technologies Limited 1.02%.... 0.06%... 19 Apr 2024
Total 1.55%
The offer not as high as CR888 was looking for when I looked last on 19th July 2023.
Tech investor Thoma Bravo agrees deal for London-listed firm
Price represents 44% premium to three-month average
Darktrace was backed by tech entrepreneur Mike Lynch
Darktrace shares jump 18%
LONDON, April 26 (Reuters) - Private equity firm Thoma Bravo agreed to buy Britain's Darktrace for $5.32 billion in cash on Friday, saying it would use its software expertise to drive growth at the Mike Lynch-backed cybersecurity company.
The agreed offer of $7.75, or around 620 pence, per share represents a 44% premium to Darktrace's three-month average share price, Thoma Bravo said.
Shares in the company, which have doubled over the last year, jumped 18% after the announcement to 608 pence.
Thoma Bravo partner Andrew Almeida said Darktrace was at the "very cutting edge" of cybersecurity.
"Thoma Bravo has been investing exclusively in software for over 20 years and we will bring to bear the full range of our platform, operational expertise and deep experience of cybersecurity in supporting Darktrace's growth," he said.
Founded in 2013 with the backing of entrepreneur Mike Lynch, Darktrace uses artificial intelligence to detect attacks and vulnerabilities inside IT networks.
Earlier in April it raised its forecasts for third time this year, reflecting demand as threats from digital attacks grows.
It listed at 250 pence in 2021.
Despite being the best performer among recent London listings, the stock has lagged U.S. peers, partly due to concerns about Lynch.
He is being tried on fraud charges in the United States over his former company Autonomy. He has denied the charges.
UNDERVALUED ON THE MARKET
Panmure Gordon analyst Harvey Robinson said the price did not reflect any significant synergies, and it could trigger interest from a trade buyer such as Palo Alto.
Thoma Bravo previously approached Darktrace in 2022 but talks did not result in an offer.
Darktrace's board rejected proposed offers from Thoma Bravo before agreeing the deal, according to the statement.
It believed its shares were undervalued and a cash offer offered certainty to investors, the statement said.
As well as commitments from Darktrace's board, Thoma Bravo said it had the backing of a KKR fund and Summit Partners. Combined they represent 14.4% of the shares.
The deal will require support from the holders of 75% of Darktrace's shares.
Thoma Bravo, which bought British software firm Sophos for $3.9 billion in 2020, said it intended to keep Darktrace headquartered in Britain.
Lynch, who has no longer has any role at Darktrace, owns 3.9% while his wife owns 2.9%, according to LSEG data.
Thoma Bravo was advised by Goldman Sachs and Darktrace was advised by Jefferies and Qatalyst Partners. (Reporting Paul Sandle in London and Yadarisa Shabong in Bengaluru and ; Editing by Mrigank Dhaniwala, Sarah Young and David Evans)
My broker has it down 9% a lesser 7.69% this site 5.71% spread. *36p
About 40 posts since last look 11 January 2024.
It has again returned to 36p as it did last week and on 11th January and 18th December 2023.
22/11/22 paid 106p for some , steady decline since then .
RNS Today
Trinity Exploration & Production - Trinidad & Tobago-focused oil exploration and production company -
Provides an update on operations for the three-month to March 31. Chief Executive Jeremy Bridglalsingh comments: "Trinity's core business remains robust and cash-generative, with no long-term debt." Focus remains on maximising cash flow from existing producing assets; rebuilding cash following the drilling of the Jacobin well in 2023; and maturing detailed engineering for the two principal projects.
24 April 2024
88 Energy Limited
SUCCESSFUL PLACEMENT TO RAISE A$9.9M
Highlights
· Completion of oversubscribed share placement to raise A$9.9 million (before costs) to domestic and international institutional and sophisticated investors at an issue price of A$0.003 per share (£0.0016 per share).
RNS listing cancelled today yesterday was last day maybe the 27% rise shorters closing .